Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations

This publication has 26 references indexed in Scilit:

• The extrahepatic contribution to HCV plasma viremia
  Journal of Hepatology, 2006
• Discovery of Small-Molecule Inhibitors of HCV NS3-4A Protease as Potential Therapeutic Agents against HCV Infection
  Current Medicinal Chemistry, 2005
• The Natural History of Hepatitis C
  Seminars in Liver Disease, 2004
• Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C
  Annals of Internal Medicine, 2004
• Projecting future complications of chronic hepatitis C in the United States
  Liver Transplantation, 2003
• New therapies on the horizon for hepatitis C: are we close?
  Clinics in Liver Disease, 2003
• Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
  New England Journal of Medicine, 2002
• Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
  Published by Elsevier ,2001
• Estimating future hepatitis C morbidity, mortality, and costs in the United States
  American Journal of Public Health, 2000
• Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis
  The Lancet, 1999